Preclinical and Clinical Efficacy of Olorinab, a Peripherally Restricted, Highly Selective Full Agonist of the Cannabinoid Type 2 Receptor for the Management of Visceral Pain in Inflammatory Bowel Disease

(1) University of Cincinnati,Cincinnati,United States

(2) Visceral Pain Research Group, Flinders University, SAHMRI,Adelaide,Australia

(3) Arena Pharmaceuticals, Inc,San Diego,United States

(4) University of Michigan,Ann Arbor,United States



This item was part of the Lower GI on fire session at UEG Week 2019

This item can be cited as: United European Gastroenterology Journal Volume 7 Issue 8 (Supplement), October 2019